Analysts Set Haleon PLC Sponsored ADR (NYSE:HLN) Target Price at $12.33

Haleon PLC Sponsored ADR (NYSE:HLN) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $12.3250.

A number of research firms recently commented on HLN. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Barclays lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th.

Institutional Trading of Haleon

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in Haleon by 22.0% in the 1st quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company’s stock worth $192,428,000 after buying an additional 3,372,155 shares during the period. Bank of America Corp DE increased its position in shares of Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after acquiring an additional 6,669,923 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after acquiring an additional 3,207,986 shares in the last quarter. Sculptor Capital LP boosted its holdings in shares of Haleon by 22.1% in the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company’s stock valued at $111,645,000 after purchasing an additional 1,962,770 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Haleon by 6.5% in the second quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock worth $81,479,000 after purchasing an additional 476,823 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 0.3%

NYSE HLN opened at $9.51 on Tuesday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon has a 52 week low of $8.71 and a 52 week high of $11.42. The firm has a market capitalization of $42.33 billion, a price-to-earnings ratio of 24.37 and a beta of 0.20. The company has a fifty day moving average of $9.37 and a two-hundred day moving average of $9.81.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.